OSR Holdings, Inc. 8-K

What Happened

• OSR Holdings, Inc. (through its subsidiary Vaximm AG) announced a binding term sheet with BCM Europe AG (BCME), the company's largest shareholder, for a proposed global exclusive, sublicensable license to Vaximm’s VXM01 oral cancer immunotherapy platform. The company filed the Form 8-K on January 14, 2026; the term sheet is dated January 13, 2026 and a press release was issued January 12, 2026.
• Under the term sheet, BCME has agreed to pay an upfront of $30.0 million (comprised of $15.0 million cash and $15.0 million in digital assets) upon execution of a definitive global license agreement, plus up to $815.0 million in aggregate clinical, regulatory, and commercial milestone payments. The term sheet contains binding provisions on the license grant, financial terms, and exclusivity; closing the definitive agreement remains subject to customary conditions, including receipt of an independent third-party fairness opinion.

Key Details

• Upfront: $30.0 million total — $15.0M cash + $15.0M in digital assets.
• Potential additional payments: up to $815.0 million in milestones tied to clinical, regulatory, and commercial events.
• Parties/dates: Term sheet between Vaximm AG and BCM Europe AG dated Jan 13, 2026; 8-K filed Jan 14, 2026.
• BCME is the largest shareholder of OSR/ Vaximm, and the agreement is subject to customary closing conditions (including a fairness opinion).

Why It Matters

• The deal, if finalized, could provide immediate non-dilutive capital ($15M cash) and significant upside via milestone payments that could materially affect future revenue potential tied to VXM01’s development and commercialization.
• Because BCME is the largest shareholder, the transaction raises potential related-party considerations; the filing notes a fairness opinion is required before the definitive agreement is executed.
• The agreement is not final — investors should note that key conditions must be satisfied before the license closes, so outcomes and timing remain uncertain. Exhibits to the 8-K include the term sheet and the company press release for more detail.